CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
9974 ETCTN A phase II study of olaparib plus cediranib in combination with standard therapy for small cell lung cancer Adult CIRB - Early Phase Emphasis
9979 ETCTN Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases Adult CIRB - Early Phase Emphasis
9984 ETCTN A Randomized Phase 2 Study of cediranib in Combination with olaparib versus olaparib alone in men with metastatic castration resistant prostate cancer Adult CIRB - Early Phase Emphasis
A011106 Alliance ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study Adult CIRB - Late Phase Emphasis
A011202 Alliance A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy Adult CIRB - Late Phase Emphasis
A011203 Alliance A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic; Estrogen Receptor Positive; HER2 Negative Breast Cancer Adult CIRB - Early Phase Emphasis
A011401 Alliance Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Adult CIRB - Late Phase Emphasis
A011502 Alliance A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Adult CIRB - Late Phase Emphasis
A011801 Alliance The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb Adult CIRB - Late Phase Emphasis
A012103 Alliance OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy Adult CIRB - Late Phase Emphasis